
United States · Pharmaceuticals startup
Xanodyne Pharmaceuticals was an integrated specialty pharmaceutical company focused on women’s healthcare and pain management.
Funding reportedLast round: Undisclosed round
Xanodyne Pharmaceuticals was an integrated specialty pharmaceutical company focused on women’s healthcare and pain management.
Founded around 2000-2001 and based in the Newport, Kentucky area, it served patients and physicians across the United States. The company developed, marketed, and distributed prescription medicines, showcasing both development and commercial capabilities. Xanodyne's product offerings included prescription pain management pharmaceuticals and a line of prenatal vitamins. Notable products included Lysteda for treating cyclic heavy menstrual bleeding, Zipsor for mild to moderate acute pain, and XP12B and XP20B for heavy menstrual bleeding and mild to moderate pain, respectively. The company also had products like Duraclon and Methadone Hydrochloride Injection, which were associated with pain management.
Funding, as reported
From the SEC filings it signed: 8 on the team.
On the board, as filediCraig A. ToomanDennis PurcellJames A. ShannonPatrick M. EnrightRolf A. ClassonSteven St. PeterVaughn M. Kailian
What they build
Known for
medicalbiotechnologyservicespharmaceuticalsb2bpain management womens healthpharmaceutical manufacturinglife sciences
Built with from their website
Google Tag ManagerViewport MetaWebSite X5Microsoft ExchangeMicrosoft 365 Apps & ServicesMobile FriendlyOpen GraphjQueryGoogle AnalyticsGoDaddy Domains
Microsoft Exchange OnlineRemoteMicrosoft 365OutlookMicrosoft Email ProvidersGoDaddy Hosting
Add your raise, your deck and your story, and put Xanodyne Pharmaceuticals in front of investors. Or tell us what we have wrong.